Four Clinical Trials have been authorized in Mexico of pharmaceutical products to eventually treat COVID-19

Abr – 01 – 2020

March 31, 2020, the Vice Secretary of Health, Hugo López-Gatell, in an official press conference, announced that the Federal Commission Against Sanitary Risks, COFEPRIS, the Mexican sanitary regulatory agency, has approved four clinical trials in relation to products to treat COVID-19:

  • Remdesivir.
  • Tocilizumab.
  • Hydroxycloriquine.
  • Chloroquine and azithromycin.

Even though these products have been used in other countries to treat COVID-19, hence, it may indicate that they are safe to treat this disease, the Mexican sanitary authorities consider that safety and efficacy of these products should be verified to treat COVID-19 and also to follow international standards to preserve biosecurity, qualitative and ethical research and to protect human beings.

OLIVARES is following closely all developments related to the current health crisis, in order to advise our clients on the legal implications of the coronavirus.

 

Share